China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu Biological Technology Co., Ltd has received IND approval from the US FDA for its recombinant shingles vaccine candidate, LZ901. The approval marks a milestone for China’s first homegrown shingles vaccine to enter global development.
Vaccine Profile
LZ901 is a recombinant vaccine featuring the herpes zoster virus glycoprotein E (gE), genetically engineered to stimulate the production of varicella antibodies. The vaccine’s unique tetramer design has shown strong immunogenicity, efficacy, and safety in preclinical studies. Its molecular structure mimics immune complexes formed during herpes zoster infection, enhancing antigen presentation and inducing robust Th1/Th2 immune responses.
Disease Background
Herpes zoster (shingles) results from reactivation of latent varicella zoster virus (VZV). With VZV IgG seroprevalence exceeding 90% in adults, a large population is at risk of developing shingles.-Fineline Info & Tech
